Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.
Chinese vaccine producer Jiangsu Recbio Technology Co., Ltd. is set to kick off the 2022 biotech initial public offerings on the Hong Kong Stock Exchange, as it seeks new funding for its business activities and pipeline development.
Amid surging global infections of the Omicron variant, the Taizhou, Jiangsu-based company hopes to highlight its COVID-19 vaccine candidates, including...
IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?
Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.
ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.
